Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
ASLN Stock: Why It Fell Over 25% Today
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development